Approval · Notice of Compliance 36731 · 2026
MRESVIA: Notice of Compliance 36731
Issued January 14, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36731
- Date
- January 14, 2026
- Company
- Moderna Biopharma Canada CorporationToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of Indication : mRESVIA (Respiratory Syncytial Virus (RSV) mRNA Vaccine) is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: • adults 60 years of age and older; • adults 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MRESVIA | Not yet assigned | — |
Medicinal ingredients
- *RSV F-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 50 MCG per 0.5ML